A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis
Condition: Systemic Lupus Erythematosus
MeSH terms: Myositis; Lupus Erythematosus, Systemic
Intervention: Sifalimumab
Intervention description: All participants will receive intravenous (IV) sifalimumab as fixed dose of 500 mg every 2 weeks (Q2W) on Day 1, Week 2, and Week 4, then every 4 weeks (Q4W) thereafter for a total of 156 weeks. The initial fixed dose of 500 mg is increased to 600 mg with subsequent protocol amendment.
Intervention MeSH terms: Sifalimumab
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 118.0
Sex: All
Minimum age: 18 Years
Maximum age: 99 Years
Healthy volunteers: No
Keywords: Sifalimumab; MEDI-545

Summary:

      The objective of this study is to assess the safety and tolerability of sifalimumab in adult
      participants with active systemic lupus erythematosus (SLE) or active dermatomyositis (DM) or
      polymyositis (PM) who participated in the following clinical studies: MI-CP151, MI-CP152, or
      MI-CP179.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 years or older at the time of screening.

          -  Written informed consent and any locally required authorization [example, Health
             Insurance Portability and Accountability Act (HIPAA) in the United States of America
             (USA), European Union (EU) Data Privacy Directive in the EU] obtained from the
             participant/legal representative prior to performing any protocol-related procedures,
             including Screening evaluations.

          -  Female participants of childbearing potential who are sexually active must use must
             use 2 effective methods of avoiding pregnancy from Screening, and must agree to
             continue using such precautions for 26 weeks after the final dose of investigational
             product.

          -  Males, unless surgically sterile, must use 2 effective methods of birth control with a
             female partner and must agree to continue using such contraceptive precautions from
             Screening until 26 weeks after the final dose of investigational product. If female,
             unless cervix has been surgically removed, have had a Pap smear with no evidence of
             malignancy within 6 months of baseline (defined as Day 1).

          -  Must have qualified for and received investigational product (sifalimumab or placebo)
             and completed the treatment period plus follow-up (through Day 266 for participants
             from MI-CP151 and MI-CP152 or through Day 168 for participants from MI-CP179) in one
             of the following sifalimumab clinical studies: MI-CP151, MI-CP152, or MI-CP179,
             ability to complete the study period through the final visit, willing to forego other
             forms of experimental drug treatment during the study.

        Exclusion Criteria:

          -  Discontinued investigational product (sifalimumab) for safety reasons from any
             previous sifalimumab clinical study.

          -  For participants with systemic lupus erythematosus (SLE): Active severe or unstable
             neuropsychiatric SLE, that in the opinion of the investigator, would make the
             participant unsuitable for the study or unable to fully understand the informed
             consent, Active severe or unstable renal disease that in the opinion of the
             investigator would make the participant unsuitable for this study

          -  For participants with dermatomyositis (DM) or polymyositis (PM): Inclusion body
             myositis, cancer-associated myositis, myositis associated with another connective
             tissue disease, environmentally-associated myositis, or drug-related myopathy, a
             history of or a family history of non-inflammatory myopathy, scapular winging,
             atrophy, or hypertrophy of the calf muscles, Active Hepatitis A, confirmed positive
             tests for hepatitis B surface antigen (HbsAg) and hepatitis B core antibody (HbcAb) or
             hepatitis C serology. Isolated HbcAb positivity will be explored with additional
             reflex testing to determine eligibility.

          -  Evidence of active tuberculosis (TB), either treated or untreated, or latent TB
             without completion of an appropriate course of treatment or appropriate ongoing
             prophylactic treatment, history of severe viral infection, such as disseminated
             herpes, herpes encephalitis, or ophthalmic herpes.

          -  Any of the following medications within 6 months before entry into the study:
             Leflunomide greater than (>) 20 milligram/day, Cyclophosphamide (or any other
             alkylating agent).

          -  Any of the following medications within 28 days before entry into the study:
             Prednisone or equivalent > 30 mg/day or > 0.5 mg/kg, whichever is the lesser amount,
             Cyclosporine at any dose, Thalidomide at any dose, Interferon alpha 2b,
             Hydroxychloroquine > 600 mg/day, Mycophenolate mofetil > 3 gram/day, Methotrexate > 25
             mg/week, Azathioprine > 3 mg/kilogram (kg)/day, Combination of leflunomide and
             methotrexate

          -  Nonstable doses of one or more of the following medications within 28 days before
             entry into the study: Hydroxychloroquine, Mycophenolate mofetil, Methotrexate,
             Azathioprine

          -  At Screening blood tests (within 28 days before entry into the study), any of the
             following: Total bilirubin > upper limit of normal (ULN), Neutrophil count <
             1,500/microliter (mcl) (or < 1.5 × 109/L), Platelet count < 60,000/microliter (mcl)
             (or < 60 × 109/L), Hemoglobin (Hgb) < 7 gram per decilitre (g/dL) (or < 70 g/L).